<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01693328</url>
  </required_header>
  <id_info>
    <org_study_id>CP057/11</org_study_id>
    <nct_id>NCT01693328</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction and Quality of Life Impact - PecFent®</brief_title>
  <acronym>Qualipec</acronym>
  <official_title>A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Archimedes Development Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Archimedes Development Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      National multicenter, prospective, observational study in cancer patients with chronic
      background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic
      condition by a specialist in the treatment of cancer pain conditions.

      • Study objectives include assessment of early treatment satisfaction.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7</time_frame>
    <description>Satisfaction will be assessed using a 4-point Likert scale.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breakthrough Cancer Pain</condition>
  <arm_group>
    <arm_group_label>PecFent®</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PecFent® (fentanyl) nasal spray</intervention_name>
    <arm_group_label>PecFent®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients with breakthrough pain
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (aged ≥18 years) with cancer

          -  Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic
             background pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Serrie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Pain Federation - Palliative Medicine Lariboisiere Hospital, Paris France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie Allouche, MD</last_name>
    <phone>+33155702320</phone>
    <email>sylvieallouchecovarrubias@archimedespharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon-Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Fayette, MD</last_name>
      <phone>+33487785451</phone>
      <email>jerome.fayette@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jerome Fayette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2012</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>PecFent</keyword>
  <keyword>Lazanda</keyword>
  <keyword>fentanyl</keyword>
  <keyword>intranasal</keyword>
  <keyword>breakthrough cancer pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

